Privacy practices using genetic data from cell-free DNA aneuploidy screening.

Area of Science:

• Genetics
• Bioethics
• Medical Informatics

Background:

• Cell-free fetal DNA (cfDNA) analysis provides highly personal genetic information for both mother and fetus.
• Understanding laboratory practices regarding cfDNA data is crucial for patient privacy and ethical data handling.

Purpose of the Study:

• To investigate how laboratories retain, use, and share genetic information derived from cfDNA.
• To assess laboratory adherence to American Society of Human Genetics (ASHG) privacy principles.
• To evaluate the readability of genetic privacy policies provided by cfDNA testing laboratories.

Main Methods:

• Identified 13 US commercial laboratories offering cfDNA aneuploidy screening.
• Collected genetic privacy policies by reviewing requisition and consent forms obtained online or directly.
• Analyzed policies for content, adherence to ASHG principles, and readability using standard metrics.

Main Results:

• 77% of laboratories used prenatal genetic information for research.
• 54% shared genetic information with external entities.
• 82% of privacy policies were written at or above a 12th-grade reading level, indicating poor readability.
• Laboratories demonstrated inadequate disclosure of privacy risks and incomplete adherence to ASHG recommendations.

Conclusions:

• Most laboratories permit prolonged use and sharing of cfDNA data, often with insufficient privacy safeguards.
• Privacy policies and consent forms are frequently written at a college reading level, hindering patient comprehension.
• Laboratories must revise consent forms, and healthcare providers should assist patients in understanding these complex documents to ensure informed consent.